[go: up one dir, main page]

UA88440C2 - ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β - Google Patents

ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β

Info

Publication number
UA88440C2
UA88440C2 UAA200501449A UA2005001449A UA88440C2 UA 88440 C2 UA88440 C2 UA 88440C2 UA A200501449 A UAA200501449 A UA A200501449A UA 2005001449 A UA2005001449 A UA 2005001449A UA 88440 C2 UA88440 C2 UA 88440C2
Authority
UA
Ukraine
Prior art keywords
glomerulonephritis
renal failure
chronic renal
interferon
therapies
Prior art date
Application number
UAA200501449A
Other languages
English (en)
Ukrainian (uk)
Inventor
Рой Р. Лобб
Original Assignee
Байоджен Айдек Ма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Айдек Ма Инк. filed Critical Байоджен Айдек Ма Инк.
Publication of UA88440C2 publication Critical patent/UA88440C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L47/00—Traffic control in data switching networks
    • H04L47/10—Flow control; Congestion control
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L47/00—Traffic control in data switching networks
    • H04L47/10—Flow control; Congestion control
    • H04L47/215—Flow control; Congestion control using token-bucket
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L47/00—Traffic control in data switching networks
    • H04L47/50—Queue scheduling
    • H04L47/62—Queue scheduling characterised by scheduling criteria
    • H04L47/6285—Provisions for avoiding starvation of low priority queues
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W28/00—Network traffic management; Network resource management
    • H04W28/02—Traffic management, e.g. flow control or congestion control
    • H04W28/0252—Traffic management, e.g. flow control or congestion control per individual bearer or channel
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W28/00—Network traffic management; Network resource management
    • H04W28/02—Traffic management, e.g. flow control or congestion control
    • H04W28/0278—Traffic management, e.g. flow control or congestion control using buffer status reports
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W72/00—Local resource management
    • H04W72/20—Control channels or signalling for resource management
    • H04W72/23—Control channels or signalling for resource management in the downlink direction of a wireless link, i.e. towards a terminal
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W8/00—Network data management
    • H04W8/02—Processing of mobility data, e.g. registration information at HLR [Home Location Register] or VLR [Visitor Location Register]; Transfer of mobility data, e.g. between HLR, VLR or external networks
    • H04W8/04—Registration at HLR or HSS [Home Subscriber Server]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W72/00—Local resource management
    • H04W72/12—Wireless traffic scheduling

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Databases & Information Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Mobile Radio Communication Systems (AREA)

Abstract

В данном изобретении предлагаются способы лечения и фармацевтические агенты для применения в лечении млекопитающих субъектов, которые имеют гломерулонефрит или хроническую почечную недостаточность, или риск их развития. Способы включают введение терапевтических агентов, которые содержат ИФН-.
UAA200501449A 2002-07-17 2003-07-17 ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β UA88440C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39639302P 2002-07-17 2002-07-17

Publications (1)

Publication Number Publication Date
UA88440C2 true UA88440C2 (ru) 2009-10-26

Family

ID=30116023

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200501449A UA88440C2 (ru) 2002-07-17 2003-07-17 ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β

Country Status (20)

Country Link
US (1) US20070025965A1 (ru)
EP (1) EP1553971A4 (ru)
JP (2) JP4883665B2 (ru)
KR (2) KR20110053390A (ru)
CN (2) CN101664545A (ru)
AU (1) AU2003256603C1 (ru)
BR (1) BR0312947A (ru)
CA (1) CA2492649A1 (ru)
EA (1) EA009938B1 (ru)
GE (1) GEP20084499B (ru)
IL (2) IL166256A (ru)
IS (1) IS7650A (ru)
MX (1) MXPA05000658A (ru)
NO (1) NO20050827L (ru)
NZ (1) NZ538217A (ru)
PL (1) PL374914A1 (ru)
RS (1) RS20050035A (ru)
UA (1) UA88440C2 (ru)
WO (1) WO2004006756A2 (ru)
ZA (1) ZA200500342B (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1811991B1 (en) 2004-11-10 2018-11-07 Genzyme Corporation Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis
HUE038947T2 (hu) 2005-08-26 2018-12-28 Ares Trading Sa Eljárás glikozilált béta-interferon elõállítására
US8604175B2 (en) 2005-12-09 2013-12-10 Ares Trading S.A. Method for purifying FSH or a FSH mutant
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
WO2007092252A2 (en) * 2006-02-03 2007-08-16 Modigene Inc Long-acting polypeptides and methods of producing same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
EP2032134B1 (en) 2006-05-09 2015-06-24 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
KR101532369B1 (ko) * 2006-12-11 2015-06-29 삼성전자주식회사 휴대용 단말기의 원격제어 장치 및 방법
EP2594562B1 (en) 2007-05-31 2016-07-20 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
WO2009045503A1 (en) 2007-10-05 2009-04-09 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
WO2009053358A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying fc-fusion proteins
US8407299B2 (en) * 2007-10-27 2013-03-26 Research In Motion Limited Content disposition system and method for processing message content in a distributed environment
CN101878043A (zh) * 2007-12-20 2010-11-03 默克雪兰诺有限公司 PEG-干扰素-β制剂
US8389517B2 (en) 2008-07-28 2013-03-05 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
CN107935983A (zh) 2008-10-03 2018-04-20 简詹姆公司 2‑酰胺基丙醇型葡糖神经酰胺合酶抑制剂
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
EP2676675B1 (en) * 2011-02-18 2019-04-10 Stemdr Inc. Composition containing inducer of sirt1 expression for preventing or treating sepsis or septic shock
WO2013157002A1 (en) 2012-04-19 2013-10-24 Prolor Biotech Inc. Long-acting oxyntomodulin variants and methods of producing same
EA033788B1 (ru) 2012-11-20 2019-11-26 Opko Biologics Ltd Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
CN107438623B (zh) 2014-12-10 2023-07-14 Opko生物科学有限公司 长效的ctp修饰的生长激素多肽的制备方法
HUE055449T2 (hu) 2015-06-19 2021-11-29 Opko Biologics Ltd Hosszú hatástartamú koagulációs faktorok és eljárások ezek elõállítására
FI126979B (en) 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and its use
TW202444744A (zh) 2016-07-11 2024-11-16 以色列商歐科生物製品有限公司 長效型凝血因子及其生產方法
RU2728696C2 (ru) * 2018-12-28 2020-07-30 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Моноклональное антитело к интерферону бета-1а человека

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997018831A1 (en) * 1995-11-17 1997-05-29 Toray Industries, Inc. Endothelial cell protective
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
ES2265693T3 (es) * 1998-10-16 2007-02-16 Biogen Idec Ma Inc. Proteinas de fusion con interferon-beta y usos.
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
EP1401484A1 (en) * 2001-06-11 2004-03-31 Transition Therapeutics Inc. Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases

Also Published As

Publication number Publication date
EA009938B1 (ru) 2008-04-28
NZ538217A (en) 2007-04-27
IL166256A0 (en) 2006-01-15
KR20050021502A (ko) 2005-03-07
KR20110053390A (ko) 2011-05-20
IL200892A0 (en) 2010-05-17
MXPA05000658A (es) 2005-08-19
RS20050035A (sr) 2007-06-04
PL374914A1 (en) 2005-11-14
EA200500218A1 (ru) 2006-08-25
WO2004006756A2 (en) 2004-01-22
IS7650A (is) 2005-01-14
WO2004006756A3 (en) 2004-08-19
CN101664545A (zh) 2010-03-10
NO20050827L (no) 2005-04-15
GEP20084499B (en) 2008-10-10
JP4883665B2 (ja) 2012-02-22
JP2011144204A (ja) 2011-07-28
CA2492649A1 (en) 2004-01-22
EP1553971A2 (en) 2005-07-20
AU2003256603C1 (en) 2010-07-15
US20070025965A1 (en) 2007-02-01
IL200892A (en) 2014-11-30
IL166256A (en) 2010-11-30
CN1681527A (zh) 2005-10-12
BR0312947A (pt) 2007-07-10
ZA200500342B (en) 2006-07-26
AU2003256603A1 (en) 2004-02-02
EP1553971A4 (en) 2006-07-05
JP2005537269A (ja) 2005-12-08
AU2003256603B2 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
UA88440C2 (ru) ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
PL371736A1 (en) Method for administering glp-1 molecules
EP1902273A4 (en) IMAGING GEOMETRY
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
SG147442A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
MY180762A (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
MXPA04006572A (es) Terapia de combinacion antivirica.
MXPA03007140A (es) Derivados de carbolina.
TW200531679A (en) Methods of modulating cytokine activity; related reagents
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
UA86749C2 (en) THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-в
EA200500774A1 (ru) Новая синергетическая комбинация, включающая рофлумиласт и формотерол
DK1214091T3 (da) Terapier til kronisk nyresvigt under anvendelse af én eller flere integrinantagonister
ATE395936T1 (de) Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten
MX2007007206A (es) Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos.
NZ514691A (en) Method to type prion proteins
MXPA05002477A (es) Asialo-interferones y el tratamiento de cancer de higado.
AP1731A (en) Use of an inhibitor of the renin-angiotensin system for the manufacture of a medicament or prevention of lipodystrophy syndorme.
UA70017A (en) Method for conservative treatment of chronic tonsillitis in adults
TW200510447A (en) Novel fusidic acid derivatives
WO2005011589A3 (en) Drug delivery methods and devices
AR103941A2 (es) Terapia de combinación para tratamiento de desórdenes neovasculares oculares
UA70188C2 (en) Method for treating patients with chronic cardiac insufficiency